Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent obtained before any trial related activities. Trial related activities are any procedures that would not have been done during normal management of the subject~2. Healthy male subjects~3. Age between 18 and 64 years, both inclusive~4. Body Mass Index (BMI) between 18.5 and 29.0 kg/m\^2, both inclusive~5. Fasting plasma glucose concentration \<= 5.5 mmol/L (100 mg/dL) at screening~6. Considered generally healthy upon completion of medical history and screening safety assessments, as judged by the Investigator~Exclusion Criteria:~1. Known or suspected hypersensitivity to IMP(s) or related product~2. Previous participation in this trial. Participation is defined as randomized~3. Receipt of any medicinal product in clinical development within 30 days before randomization in this trial~4. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction~5. Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator~6. Any history or presence of clinically relevant comorbidity, as judged by the Investigator~7. Signs of acute illness as judged by the Investigator~8. Any serious systemic infectious disease during four weeks prior to first dosing of the trial drug, as judged by the Investigator~9. Clinically significant abnormal screening laboratory tests, as judged by the Investigator~10. Elevation of serum ALT\> 10% above the ULN, or elevation of serum AST or serum bilirubin \>20% above the ULN. (Note: Elevation of bilirubin is considered acceptable in case of Gilbert's disease and should be evaluated in clinical context)~11. Elevation of serum creatinine \> ULN, or elevation of serum urea \> 10% above ULN~12. Systolic blood pressure \< 90 mmHg or \>139 mmHg and/or diastolic blood pressure \< 50 mmHg or \> 89 mmHg (one repeat test will be acceptable in case of suspected white-coat hypertension)~13. Symptoms of arterial hypotension~14. Heart rate at rest outside the range of 50-90 beats per minute~15. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator~16. Increased risk of thrombosis, e.g. subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator~17. Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 24 grams alcohol/day (on average)~18. A positive result in the alcohol and/or urine drug screen at the screening visit~19. Smoking more than 5 cigarettes or the equivalent per day~20. Inability or unwillingness to refrain from smoking and use of nicotine substitute products one day before and during the inpatient period~21. Positive test for Hepatitis Bs antigen~22. Positive test for Hepatitis C antibodies. (Presence of Hepatitis C antibodies will not lead to exclusion if liver function tests are normal and a hepatitis C polymerase chain reaction is negative)~23. Positive result to the test for HIV-1/2 antibodies or HIV-1 antigen~24. Any medication (prescription and non-prescription drugs) within 7 days before IMP administration and/or anticoagulant therapy~25. Blood donation or blood loss of more than 500mL within the last 3 months~26. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation~Explanatory note on Exclusion Criterion 24: With the exception of paracetamol or NSAIDs for occasional use to treat acute pain, as judged by the Investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Gan & Lee Insulin Lispro Injection (Type: EXPERIMENTAL): Insulin lispro, 3 mL cartridge in prefilled pen, 100 units/mL (U-100)
- EU - approved Humalog ® (Type: ACTIVE_COMPARATOR): Insulin lispro (product approved and marketed in the EU), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)
- US - licensed Humalog ® (Type: ACTIVE_COMPARATOR): Insulin lispro (product approved and marketed in the US), 3 mL cartridge in prefilled Kwikpen®, 100 units/mL (U-100)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete